Pfizer, BioNTech to Sell Further 200 Million Covid-19 Vaccine Doses to U.S. Government
July 23 2021 - 7:32AM
Dow Jones News
By Robb M. Stewart
Pfizer Inc. and BioNTech SE have agreed to supply an additional
200 million doses of their Covid-19 vaccine to the U.S. government,
bringing the total under their existing supply agreement to 500
million doses.
The additional doses that will be bought will help the U.S.
government ensure broad vaccine access into next year, said Albert
Bourla, chairman and chief executive of Pfizer.
The companies said they expect to deliver 110 million of the
additional doses by the end of the year, and the remaining 90
million no later than April 30, 2022.
The U.S. government also has the option to buy an updated
version of the vaccine to address potential variants as well as new
formulations of the vaccine, if available and authorized, the
companies said. Eligible U.S. residents will continue to receive
the vaccine for free, under a government commitment for free access
to Covid-19 vaccines.
The Pfizer-BioNTech Covid-19 vaccine hasn't been approved or
licensed by the U.S. Food and Drug Administration, but the agency
has authorized it for emergency use.
In June, Pfizer and BioNTech said they planned to provide the
U.S. government with 500 million doses of their Covid-19 vaccine
for donation to the world's poorest nations.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
July 23, 2021 07:23 ET (11:23 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024